DBVT vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 19, 2026

DBVT

51.2
AI Score
VS
MRNA Wins

MRNA

52.9
AI Score

Investment Advisor Scores

DBVT

51score
Recommendation
HOLD

MRNA

53score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DBVT MRNA Winner
Revenue 1.60M 534.00M MRNA
Net Income -98.00M -2.13B DBVT
Net Margin -6125.0% -397.9% MRNA
Operating Income -98.50M -2.20B DBVT
ROE -61.1% -31.4% MRNA
ROA -43.9% -19.4% MRNA
Total Assets 223.20M 10.96B MRNA
Cash 174.90M 1.72B MRNA
Current Ratio 3.72 2.29 DBVT
Free Cash Flow -102.50M -1.25B DBVT

Relative Price Performance (Last 90 Days)

DBVT 1M: -13.2% · 3M: -21.6% MRNA 1M: +25.8% · 3M: +199.3%

Current Technical Phase

DBVT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -8.4%), weak momentum, RSI 44

RSI (14): 44.4 · Price: $12.63

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (47.8% over 20 days), RSI 72

RSI (14): 72.2 · Price: $182.56

Fundamentals Snapshot

Metric DBVT MRNA
Market Cap
Forward P/E -29.2 -38.1
Trailing P/E
Revenue (TTM)
Revenue Growth -0.5% 0.0%
Gross Margin 1.0% -0.7%
Operating Margin -72.3% -5.6%
EPS -3.50 -7.98
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.